Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Organigram Global Inc. is a Canada-based cannabis company operating primarily in the legal recreational and medical cannabis industry, with an increasing focus on international markets and cannabinoid-based product development. The company’s core activities include the cultivation, processing, and sale of dried flower, pre-rolls, vapes, edibles, and other cannabis-derived products. Its revenue is predominantly generated from the Canadian adult-use market, supplemented by medical cannabis sales and strategic investment income.
The company is positioned as a branded cannabis producer with scale in indoor cultivation and product innovation, supported by automation and controlled-environment growing capabilities. Originally founded in 2013 and publicly listed in 2016, the company evolved from a regional licensed producer into a national cannabis supplier. In 2023, it formally rebranded from Organigram Holdings Inc. to Organigram Global Inc., reflecting its stated intent to expand internationally and diversify beyond the Canadian market.
Business Operations
Organigram Global Inc. operates through its primary wholly owned subsidiary, Organigram Inc., which manages cultivation, manufacturing, and commercialization activities in Canada. The company generates revenue through wholesale and direct sales to provincial cannabis distributors and medical patients, with a product portfolio spanning multiple price tiers and consumer segments. Its Canadian operations are supported by large-scale indoor cultivation facilities and in-house product development.
Internationally, Organigram maintains limited commercial exposure but has strategic interests in research, intellectual property, and potential future market entry. The company also controls Motif Labs Ltd., an acquired Canadian licensed producer focused on extraction, pre-roll manufacturing, and value-oriented cannabis products. Organigram has disclosed collaborative arrangements and minority interests intended to support innovation and optionality in emerging cannabinoid technologies, though revenue contribution from these initiatives remains secondary.
Strategic Position & Investments
Organigram’s strategic direction emphasizes profitability, operational efficiency, and brand-led growth within the Canadian cannabis market, while using strategic capital to build long-term international options. A key element of this strategy is a significant equity investment by a wholly owned subsidiary of British American Tobacco, which provided capital earmarked for product innovation and global expansion initiatives. This investment also led to the formation of Jupiter Research Ltd., a research-focused entity dedicated to developing next-generation cannabis and cannabinoid products.
The company has pursued selective acquisitions to strengthen its domestic competitive position, most notably the acquisition of Motif Labs Ltd., which expanded Organigram’s manufacturing capabilities and value-brand offerings. Organigram has also disclosed investments and partnerships aimed at gaining exposure to international cannabis and wellness markets; however, the scale, timing, and ultimate commercial impact of these initiatives remain uncertain based on available public disclosures.
Geographic Footprint
Organigram Global Inc. is headquartered in Canada, with primary operations and revenue generation concentrated in the Canadian market. Its cultivation, manufacturing, and distribution activities are located within Canada and serve provincial cannabis boards and medical patients nationwide. Canada remains the company’s most significant geographic region by revenue and assets.
Beyond Canada, Organigram maintains a strategic international footprint through research entities, minority investments, and early-stage commercial relationships. These activities provide exposure to international markets, including parts of Europe, the Middle East, and Asia-Pacific, though operational control and material revenue outside Canada are limited. Public disclosures indicate that international operations are primarily investment- and research-oriented rather than full-scale commercial production.
Leadership & Governance
Organigram Global Inc. is led by an executive team with experience in consumer packaged goods, regulated industries, and capital markets. The leadership emphasizes disciplined capital allocation, operational efficiency, and brand development as core elements of the company’s strategic vision. Governance is overseen by a board of directors with a mix of cannabis, consumer, and financial expertise.
Key executives include:
- Beena Goldenberg – Chief Executive Officer
- Paolo De Luca – Chief Financial Officer
- Kirsten Hastings – Chief Commercial Officer
- Larry Kane – Chief Operating Officer
- Ethan MacDonald – Chief Corporate Development Officer
The executive team has articulated a strategy centered on achieving sustainable profitability in Canada while leveraging strategic partnerships and investments to support long-term global growth.